Risperidone, 2 mg 20 pcs

Risperidone is an antipsychotic (neuroleptic), a benzisoxazole derivative. It also has sedative, antiemetic and hypothermic effects. Selective monoaminergic antagonist, has high tropism to serotonergic 5-HT2 and dopaminergic D2 receptors. It also binds to alpha1-adrenoreceptors with slightly lower affinity to H1-histaminergic and alpha2-adrenergic receptors. It has no tropinity to cholinoreceptors.

Antipsychotic action is caused by blockade of dopamine D2-receptors of mesolimbic and mesocortical system. Sedative action is caused by blockade of adrenoreceptors of reticular formation of brain stem; antiemetic action – by blockade of dopamine D2-receptors of trsternal zone of vomiting center; hypothermic action – by blockade of dopamine receptors of hypothalamus.

Suppresses productive symptomatology (delirium, hallucinations, aggression), automatism. Causes less suppression of motor activity and is less likely to induce catalepsy than classical antipsychotic drugs (neuroleptics). Balanced central antagonism to serotonin and dopamine may reduce the propensity for extrapyramidal side effects and extend the therapeutic effects of the drug to include negative and affective symptoms of schizophrenia.
May induce a dose-dependent increase in plasma prolactin concentration.

Pharmacokinetics

Absorption is rapid and complete. Food has no effect on the completeness and rate of absorption. ÒCmax of risperidone is 1 hour, of 9-hydroxyrisperidone – 3 hours (with high activity of CYP2D6 isoenzyme) and 17 hours (with low activity of CYP2D6 isoenzyme). Plasma concentrations of risperidone are proportional to the dose of the drug. The equilibrium concentration of risperidone in most patients is reached within 1 day, 9-hydroxy-risperidone – after 4-5 days.

Risperidone is rapidly distributed in the body. It penetrates the central nervous system (CNS), breast milk. The volume of distribution is 1-2 l/kg. Binding with plasma proteins (with alpha1-acid glycoprotein and albumin) of risperidone is 90%, that of 9-hydroxyrisperidone – 77%.

It is metabolized by CYP2D6 isoenzyme to the active metabolite, 9-hydroxysperidone (risperidone and 9-hydroxysperidone constitute the active antipsychotic fraction). Another route of metabolism of risperidone is N-dealkylation.
The half-life of risperidone is 3 hours; 9-hydroxyrisperidone and the active antipsychotic fraction is 20-24 hours.
Excreted by the kidneys (70%: of which 35-45% – as pharmacologically active fraction) and intestines (14%).

The study of single administration of the drug showed higher plasma concentration and slower excretion in elderly patients and patients with renal insufficiency. Excretion is slower in elderly patients and in patients with renal failure.

In case of hepatic impairment plasma content of risperidone is increased by 35%.

Indications

• chizophrenia (acute and chronic) and other psychotic conditions with productive and/or negative symptoms;
• affective disorders in various mental illnesses;
• .
• behavioral disorders in patients with dementia in the manifestation of symptoms of aggression (outbursts of anger, physical violence), in disorders of mental activity (agitation, delirium) or psychotic symptoms;
• as adjunctive therapy in the treatment of mania in bipolar disorders;
• as adjunctive therapy for conduct disorder in adolescents from 15 years and adult patients with reduced intellectual level or mental retardation, in cases where destructive behavior (aggressiveness, impulsivity, autoaggression) is leading in the clinical picture of disease.

Active ingredient

Risperidone

Composition

Active ingredient:

risperidone 2 mg;

Supplements:

calcium hydrophosphate dihydrate,

povidone (plasdon K 29/32 or collidone 30),

pregelatinized starch (C*Pharm starch),

magnesium stearate,

p> microcrystalline cellulose;

Composition of the film coating:

selekoate AQ-02003 (hypromellose 2910 (hydroxypropyl-methylcellulose 2910), macrogol-6000 (polyethylene glycol 6000), titanium dioxide).

How to take, the dosage

It is administered orally. In adults and children over 15 years of age it is prescribed 1 or 2 times a day.

Schizophrenia. The initial dose is 2 mg per day. On day 2, up to 4 mg per day. From then on, if necessary, the dose can either be kept at the same level or adjusted individually in the range of 4-6 mg per day.

Doses above 10 mg daily have not been shown to be more effective than lower doses and may cause extrapyramidal symptoms. The maximum daily dose is 16 mg.

Behavioral disorders in patients with dementia: The optimal dose is 1 mg once daily.

Bipolar disorders in mania: The initial dose is 2 mg 1 time per day. Increase the dose (by 2 mg per day) – not more often than every other day. The optimal dose is 2-6 mg per day.

Behavioral disorders in patients with mental retardation or with destructive tendencies dominating in the clinical picture. Patients with a body weight of 50 kg or more. The optimal dose is 1 mg per day.

It is recommended that both the starting dose and subsequent dose increases in elderly patients and in patients with renal or hepatic impairment be reduced by a factor of 2 (if adequate dosage form is necessary).

Interaction

Risperidone decreases the effectiveness of levodopa and dopamine agonists. Phenothiazines, tricyclic antidepressants and beta-adrenoblockers increase the plasma concentration of risperidone (does not affect the concentration of the active antipsychotic fraction).

Concomitant administration of carbamazepine and other inducers of microsomal enzymes decreases the concentration of the active antipsychotic fraction of risperidone in plasma. Clozapine decreases clearance of risperidone.

When used concomitantly with risperidone, ethanol, drugs that depress the central nervous system (CNS) lead to additive suppression of CNS function.

Hypotensive drugs increase the severity of BP reduction with risperidone.

Fluoxetine may increase the plasma concentration of risperidone (to a lesser extent, its active antipsychotic fraction).

.

Special Instructions

In schizophrenia, at the beginning of treatment with risperidone, it is recommended that previous therapy be gradually withdrawn if clinically warranted. If patients are transferred from therapy with depot forms of antipsychotic medication, it is recommended that administration be started instead of the next scheduled injection. The need for continuation of current antiparkinsonian drug therapy should be evaluated periodically.

The risk of mania or hypomania can be significantly reduced with low doses of risperidone or with gradual increases.
If orthostatic hypotension occurs, especially during the initial period of dose adjustment, dose reduction should be considered. In patients with diseases of the cardiovascular system, as well as in dehydration, hypovolemia or cerebrovascular disorders, the dose of risperidone should be increased gradually. If signs and symptoms of tardive dyskinesia occur, withdrawal of all antipsychotic medications should be considered. In malignant neuroleptic syndrome – all antipsychotic medications, including risperidone, should be withdrawn.

When withdrawing carbamazepine and other microsomal enzyme inducers, the dose of risperidone should be reduced.

Patients should be advised to refrain from overeating due to the possibility of weight gain.

During treatment, caution should be exercised when driving vehicles and engaging in other potentially hazardous activities requiring increased concentration and quick psychomotor reactions.

.

Contraindications

• hypersensitivity
• lactation period
• childhood (under 15 years) – effectiveness and safety have not been established.

With caution: Used in brain tumor, intestinal obstruction, drug overdose, Reye syndrome (the antiemetic effect of risperidone may mask the symptoms of these conditions), diseases of the cardiovascular system (chronic heart failure, atrioventricular block, myocardial infarction), dehydration, disorders of the brain circulation, hypovolemia, Parkinson’s disease, convulsions (incl.

Parkinson’s disease, seizures (including history), drug abuse, drug addiction, severe renal failure, severe hepatic failure, conditions predisposing to development of pirouette-type tachycardia (bradycardia, electrolyte imbalance, concomitant use of QT interval prolonging drugs), pregnancy.

.

Side effects

Central nervous system disorders: insomnia, agitation, anxiety, headache, somnolence, increased fatigability, dizziness, decreased ability to concentrate, blurred vision, extrapyramidal symptoms (tremor, rigidity, hypersalivation, bradykinesia, akathisia, acute dystonia), mania or hypomania, stroke (in elderly patients with predisposing factors). In schizophrenic patients – hypervolemia (either due to polydipsia or due to inadequate antidiuretic hormone secretion syndrome), tardive dyskinesia (involuntary rhythmic movements, mainly of the tongue and/or face), malignant neuroleptic syndrome (hyperthermia, muscle rigidity, instability of autonomic functions, impaired consciousness and increased creatinphosphokinase activity), thermoregulation disorders, epileptic seizures.

Digestive system disorders: constipation, dyspepsia, nausea or vomiting, abdominal pain, increased liver transaminase activity, dry mouth, hyposalivation or hypersalivation, anorexia.

Cardiovascular system: orthostatic hypotension, reflex tachycardia or increased blood pressure (BP).

Hematopoietic disorders: neutropenia, thrombocytopenia.

Endocrine system disorders: galactorrhea, gynecomastia, menstrual irregularities, amenorrhea, weight gain or loss, hyperglycemia or exacerbation of pre-existing diabetes.

Urogenital system disorders: priapism, erectile dysfunction, ejaculation disorders, orgasm disorders, including anorgasmia, urinary incontinence.

Allergic reactions: itching, rash, angioedema.

Skin disorders: dry skin, hyperpigmentation, seborrhea, photosensitization.

Others: arthralgia, rhinitis.

.

Overdose

Symptoms: drowsiness, sedation, tachycardia, decreased BP, extrapyramidal disorders, rarely – QT interval prolongation.

Treatment: ensure free airway to ensure adequate oxygen supply and ventilation, gastric lavage (after intubation if unconscious) and administration of activated charcoal along with laxatives. Immediately begin ECG monitoring to detect possible arrhythmias.

There is no specific antidote. Symptomatic therapy aimed at maintenance of vital body functions should be carried out. In case of BP decrease and vascular collapse – intravenous infusion of infusion solutions and/or adrenostimulants. In case of development of acute extrapyramidal symptoms – anticholinergic drugs.

Continuous medical observation and monitoring should be continued until the symptoms of intoxication disappear.

Similarities

Risolept Consta, Torendo Ku-tab, Risperidone